Waiving patent rights on COVID-19 vaccines and drugs is still crucial to ensure access globally, but the waiver on the table at the June World Trade Organization meeting doesn’t do the job.
A highlight of this pandemic is how quickly effective vaccines were developed and rolled out.
CORBEVAX is anticipated to significantly expand vaccine access to people in low- and middle-income countries.
The new variant threatens to infect billions worldwide in early 2022.
In places with low vaccination rates, COVID-19 has the chance to linger, and variants develop and travel. Without global vaccine equity, this entirely predictable pattern will repeat itself.
With low COVID vaccination coverage in southern Africa, some have suggested global vaccine inequities may be responsible for the emergence of Omicron.
Achieving widespread immunity to COVID-19 through vaccination requires as many people as possible to get their shots, including those who object or haven’t bothered.
Are vaxxies just the latest trend in virtue signalling? And even if they are, does that mean they’re not worth it?
Hotspot neighbourhoods with greater COVID-19 risk exposure continued to have higher infection rates even when they achieved vaccination levels equal to lower-risk neighbourhoods.
Much remains to be resolved before the waiver is translated into increased vaccine supply.
Due to early logistical planning, Rwanda had the capacity to store 5 million doses before the vaccines arrived.